Trial intelligence / Profile preview

PXT3003 in Charcot-Marie-Tooth Disease Type 1A

NCT01401257Phase 2Completed

Sponsor
Pharnext
Start
Dec 2010
Primary completion
Oct 2011
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of PXT 3003 in Charcot-Marie-Tooth disease type 1A (CMT1A), sponsored by Pharnext. Started Dec 2010; status: completed.

02

Drugs

PXT 3003
03

Conditions

Charcot-Marie-Tooth disease type 1A (CMT1A)

Beyond the preview

Go deeper on NCT01401257.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01401257.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call